Cargando…

Combination of T-DM1 and platinum-based chemotherapy in patient-derived xenograft models of muscle-invasive bladder cancer

OBJECTIVE(S): To assess the efficacy and safety of T-DM1, as an anti-HER2 antibody-drug conjugate (ADC), alone and in combination with two platinum-based chemotherapy regimens in patient-derived xenografts (PDXs) of muscle-invasive bladder cancer (MIBC) established in immunodeficient mice. MATERIALS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Razzaghdoust, Abolfazl, Muhammadnejad, Samad, Parvin, Mahmoud, Bahram, Bahram, Zangeneh, Masoumeh, Basiri, Abbas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mashhad University of Medical Sciences 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9392562/ https://www.ncbi.nlm.nih.gov/pubmed/36033955 http://dx.doi.org/10.22038/IJBMS.2022.63509.14005

Ejemplares similares

Development and immunohistochemical characterization of patient-derived xenograft models for muscle invasive bladder cancer
por: Razzaghdoust, Abolfazl, et al.
Publicado: (2021)

Data-Driven Discovery of Molecular Targets for Antibody-Drug Conjugates in Cancer Treatment
por: Razzaghdoust, Abolfazl, et al.
Publicado: (2021)

Association of immunohistochemical markers of tumor subtype with response to neoadjuvant chemotherapy and survival in patients with muscle-invasive bladder cancer
por: Razzaghdoust, Abolfazl, et al.
Publicado: (2021)

A comparative study of cisplatin-based definitive chemo-radiation in non-metastatic squamous cell carcinoma of the esophagus
por: Mofid, Bahram, et al.
Publicado: (2016)

Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer
por: Guancial, Elizabeth A., et al.
Publicado: (2016)

Changes in Lean Muscle Mass Associated with Neoadjuvant Platinum-Based Chemotherapy in Patients with Muscle Invasive Bladder Cancer
por: Rimar, Kalen J., et al.
Publicado: (2018)

LINC00857 expression predicts and mediates the response to platinum‐based chemotherapy in muscle‐invasive bladder cancer
por: Dudek, Aleksandra M., et al.
Publicado: (2018)

Spontaneous xenogeneic GvHD in Wilms' tumor Patient‐Derived xenograft models and potential solutions
por: Monzavi, Seyed Mostafa, et al.
Publicado: (2022)

AGS cell line xenograft tumor as a suitable gastric adenocarcinoma model: growth kinetic characterization and immunohistochemistry analysis
por: Barati, Tahereh, et al.
Publicado: (2018)

Patient-derived xenograft (PDX) models, applications and challenges in cancer research
por: Abdolahi, Shahrokh, et al.
Publicado: (2022)

Evaluation of direct intramural injection to the bladder wall as a method for developing orthotopic tumor models
por: Bitaraf, Masoud, et al.
Publicado: (2022)

Intravesical chemotherapy in non-muscle-invasive bladder cancer
por: Porten, Sima P., et al.
Publicado: (2015)

Minimally Invasive Establishment of Murine Orthotopic Bladder Xenografts
por: Jäger, Wolfgang, et al.
Publicado: (2014)

Anti‐inflammatory effect of mesenchymal stem cells on hepatocellular carcinoma in the xenograft mice model
por: Hajighasemlou, Saieh, et al.
Publicado: (2022)

Risk based neoadjuvant chemotherapy in muscle invasive bladder cancer
por: Jayaratna, Isuru S., et al.
Publicado: (2015)

Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer
por: Liu, David, et al.
Publicado: (2017)

Immune Responses to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer
por: Sherif, Amir, et al.
Publicado: (2018)

Determinants of neoadjuvant chemotherapy use in muscle-invasive bladder cancer
por: Carvalho, Filipe LF., et al.
Publicado: (2020)

Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma
por: Baras, Alexander S., et al.
Publicado: (2015)

Bladder preservation by neoadjuvant chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer
por: Elsayed, Dalia Hamouda, et al.
Publicado: (2023)

Trends in utilization of neoadjuvant and adjuvant chemotherapy for muscle invasive bladder cancer
por: McFerrin, Coleman, et al.
Publicado: (2020)

Predicting Complete Response to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer
por: Miyagi, Hiroko, et al.
Publicado: (2022)

Correction: Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma
por: Baras, Alexander S., et al.
Publicado: (2015)

Chemotherapy of human head and neck cancer xenografts with three clinically active drugs: cis-platinum, bleomycin and methotrexate.
por: Braakhuis, B. J., et al.
Publicado: (1983)

Renal mucormycosis following transurethral resection of prostate in the time of COVID-19: Unique imaging features resembling emphysematous pyelonephritis
por: Basiri, Abbas, et al.
Publicado: (2022)

Efficacy of Bladder Intravesical Chemotherapy with Three Drugs for Preventing Non-Muscle-Invasive Bladder Cancer Recurrence
por: Zhang, Jianglei, et al.
Publicado: (2021)

Neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer: The likelihood of initiation and completion
por: Eldefrawy, Ahmed, et al.
Publicado: (2012)

Peri-operative chemotherapy for muscle-invasive bladder cancer: status-quo in 2017
por: Pradère, Benjamin, et al.
Publicado: (2017)

Contemporary best practice in the use of neoadjuvant chemotherapy in muscle-invasive bladder cancer
por: Marcq, Gautier, et al.
Publicado: (2019)

Estimating the optimal perioperative chemotherapy utilization rate for muscle‐invasive bladder cancer
por: Karim, Safiya, et al.
Publicado: (2019)

Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer
por: D’Andrea, David, et al.
Publicado: (2021)

Neoadjuvant versus Adjuvant Chemotherapy in Patients with Resectable Muscle-Invasive Bladder Cancer
por: Sawasdee, Anupong, et al.
Publicado: (2022)

Low adherence to recommended use of neoadjuvant chemotherapy for muscle-invasive bladder cancer
por: van Hoogstraten, Lisa M. C., et al.
Publicado: (2023)

Characterization and Validation of Hepatocellular Carcinoma (HCC) Xenograft tumor as a Suitable Liver Cancer Model for Preclinical Mesenchymal Stem Cell Studies
por: Hajighasemlou, Saieh, et al.
Publicado: (2018)

Prognostic impact of Schlafen 11 in bladder cancer patients treated with platinum‐based chemotherapy
por: Taniyama, Daiki, et al.
Publicado: (2021)

Neoadjuvant chemotherapy with gemcitabine and cisplatin followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of bladder
por: Sung, Hyun Hwan, et al.
Publicado: (2022)

Impact of intravesical Bacillus Calmette-Guérin and chemotherapy on the bladder microbiome in patients with non-muscle invasive bladder cancer
por: James, Christopher, et al.
Publicado: (2023)

Characterizing treatment resistance in muscle invasive bladder cancer using the chicken egg chorioallantoic membrane patient-derived xenograft model
por: Villanueva, Hugo, et al.
Publicado: (2022)

Bladder Preservation for Muscle Invasive Bladder Cancer
por: Mirza, Arafat, et al.
Publicado: (2016)

Neoadjuvant Chemotherapy in Invasive Bladder Cancer
por: Oliver, R.T.D.
Publicado: (1991)

Cannot write session to /tmp/vufind_sessions/sess_a50qfcgbe4a2t56kla5v7sca8j